SCHEMBL17809552

SCHEMBL17809552

COc1ccc(-c2ccc3c(c2)CCCN3C)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.47
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
KMT2A Q03164 1/20 0.45
TNF P01375 2/20 0.44
HSD17B1 P14061 1/20 0.44
HSD17B2 P37059 1/20 0.44
WDR5 P61964 1/20 0.43
OTUD7B Q6GQQ9 2/20 0.43
CYP11B1 P15538 3/20 0.42
CYP11B2 P19099 3/20 0.42
AVPR2 P30518 1/20 0.41
AVPR1A P37288 1/20 0.41
AVPR1B P47901 1/20 0.41
CYP2A6 P11509 1/20 0.40
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17809803 0.87 MAPT (0.43) USP30MEN1ALDH1A1GAAMAPT
SCHEMBL17809643 0.84 CHRNA7 (0.46) USP30MEN1ALDH1A1GAAMAPT
SCHEMBL17806223 0.84 USP30 (0.45) USP30TNFHSD17B1HSD17B2OTUD7B
SCHEMBL19368891 0.84 HRH3 (0.46) USP30TNFHSD17B1HSD17B2OTUD7B
SCHEMBL17809777 0.82 CYP11B2 (0.48) MEN1ALDH1A1GAAMAPTHPGD
SCHEMBL17809769 0.81 WDR5 (0.48) MEN1ALDH1A1GAAMAPTHPGD
SCHEMBL20245357 0.80 CYP11B2 (0.50) CYP11B2
SCHEMBL21254924 0.80 USP30 (0.42) USP30TNFHSD17B1HSD17B2OTUD7B
SCHEMBL17809653 0.80 USP30 (0.40) USP30HPGDTNFCYP11B2PIK3CA
SCHEMBL17809561 0.79 MEN1 (0.45) MEN1ALDH1A1GAAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 USP30 2156/4885MEN1 1426/4885ALDH1A1 1727/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 USP30 2156/4885MEN1 1426/4885ALDH1A1 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.